Head-to-head evidence
Carisbamate vs Eslicarbazepine acetate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
The study was randomized and double-blind with 566 participants, and its primary endpoint was the clinical measure of change in seizure frequency. However, no results are posted and the registry record does not clearly identify a comparator arm, so the primary endpoint cannot be judged as met or missed.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
The main study was randomized, quadruple-blind, placebo-controlled, and included 402 participants, with seizure frequency as a clinical primary endpoint. Although seizure frequency was lower in all eslicarbazepine groups than with placebo, the posted registry data do not state whether the prespecified primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Eslicarbazepine acetate's landscape